Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3325656 in Healthy Subjects and Patients with Type 2 Diabetes
NCT03115099Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3325656 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) at 5 weeks. Started May 2017; status: completed.
02
Drugs
LY3325656
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03115099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115099.